First-in-human phase I/IIa clinical trial of ZV0203, a novel pertuzumab-based antibody-drug conjugate (ADC), in patients (pts) with Her2 positive advanced solid

被引：1

作者：

Lin, F. ^{[1
]}

Huang, Y. ^{[2
]}

Lu, Y. ^{[2
]}

Rao, X. ^{[3
]}

Wang, X. ^{[2
]}

Wang, F. ^{[2
]}

Huang, X. ^{[2
]}

机构：

[1] Tongji Univ, Shanghai East Hosp, Med Oncol, Shanghai, Peoples R China

[2] Hangzhou Adcoris Biopharma Co Ltd, Translat Med, Hangzhou, Peoples R China

[3] Nanchang Univ, Affiliated Hosp 1, Med Oncol, Nanchang, Jiangxi, Peoples R China

来源：

关键词：

D O I：

10.1016/j.annonc.2024.08.274

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

335P

引用

页码：S354 / S355

页数：2